此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

老年患者急性缺血性卒中治疗的低剂量替奈普酶 (DATE-AGING)

2026年11月1日 更新者:Zhenhua Zhou、Southwest Hospital, China

低剂量替奈普酶治疗老年急性缺血性卒中患者的疗效与安全性:一项前瞻性、多中心、随机对照研究

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

研究概览

研究类型

介入性

注册 (实际的)

806

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Anshan、中国
        • Anshan Changda Hospital
      • Anyang、中国
        • Anyang People's Hospital
      • Anyang、中国
        • Huaxian People's Hospital of Henan
      • Baoshan、中国
        • Baoshan People's Hospital
      • Bijie、中国
        • People's Hospital of Zhijin County
      • Chongqing、中国
        • Chongqing University Three Gorges Hospital
      • Chongqing、中国
        • Chongqing University Jiangjin Hospital
      • Chongqing、中国
        • Bishan Hospital
      • Chongqing、中国
        • Chongqing Emergency Medical Center
      • Chongqing、中国
        • Chongqing University Fuling Hospital
      • Chongqing、中国
        • Dianjiang People's Hospital OF Chongqing
      • Chongqing、中国
        • People's Hospital Of Xiushan County
      • Chongqing、中国
        • The People's Hospital of Dazu Chongqing
      • Chongqing、中国
        • The People's Hospital of HeChuan, Chongqing
      • Chongqing、中国
        • The People's Hospital of Rongchang Chongqing
      • Chongqing、中国
        • The People's Hospital of Tongnan District Chongqing City
      • Chongqing、中国
        • The Seventh People's Hospital of Chongqing
      • Chongqing、中国
        • Tongliang Hospital
      • Chongqing、中国
        • Yunyang County People's Hospital
      • Dali、中国
        • Dali Bai Autonomous Prefecture People's Hospital
      • Dazhou、中国
        • Dazhou Central Hospital
      • Deyang、中国
        • The People's Hospital of Zhongjiang
      • Guang’an、中国
        • Guang an People's Hospital
      • Guiyang、中国
        • Guizhou Provincial People's Hospital
      • Guiyang、中国
        • The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
      • Ha’erbin、中国
        • The First Affiliated Hospital of Harbin Medical University
      • Hebi、中国
        • Xunxian People's Hospital
      • Heyuan、中国
        • Heyuan People's Hospital
      • Huanggang、中国
        • Qichun People's Hosiptal
      • Jianyang、中国
        • The People's Hospital Of Jianyang City
      • Laixi、中国
        • Laixi People's Hospital
      • Leshan、中国
        • People's Hospital of Leshan
      • Leshan、中国
        • Leshan Geriatric Specialized Hospital
      • Luoyang、中国
        • Luoyang Mengjin People's Hospital
      • Nanchong、中国
        • Nanbu People's Hospital
      • Pujiang、中国
        • Puyang People's Hospital
      • Pujiang、中国
        • The People's Hospital of Nan Le Xian
      • Shangqiu、中国
        • People's Hospital of Ningling County
      • Shangqiu、中国
        • The First People's Hospital of Shangqiu
      • Shaoyang、中国
        • The First People ' S Hospital of Shao Yang
      • Shijiazhuang、中国
        • The People's Hospital of Gaocheng
      • Wuhan、中国
        • Wuhan Puren Hospital
      • Xiangyang、中国
        • Xiangyang NO.1 People's Hospital
      • Yibin、中国
        • The second people's hospital of Yibin
      • Zhumadian、中国
        • Zhumadian Central Hospital
      • Zhuzhou、中国
        • Zhuzhou Central Hospital
      • Zigong、中国
        • Zigong Third People's Hospital
      • Ziyang、中国
        • Ziyang Central Hospital
    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、400038
        • Southwest Hospital, Chongqing, China
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150200
        • Wuchang People's Hospital
    • Henan
      • Zhoukou、Henan、中国、466300
        • Shenqiu County People's Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

70年 及以上 (年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age ≥ 70 years;
  2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
  3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
  4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
  5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
  6. Informed consent from the patient or surrogate.

Exclusion Criteria:

  1. Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);

  2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to

    • Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
    • Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
    • Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
    • Platelet count of below 100×10^9/ L
    • Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
    • Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
    • Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
    • Neoplasm with increased haemorrhagic risk
    • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
    • History of significant trauma or major surgery within the past 3 months.
    • Any known disorder associated with a significant increased risk of bleeding
  3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

  4. Blood glucose <2.8 mmol/L or >22.22 mmol/L;

  5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;

  6. Seizure at stroke onset;

  7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;

  8. Participation in other clinical trials within 3 months prior to screening;

  9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Low-Dose Tenecteplase

0.175mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient.

有源比较器:Standard-Dose Tenecteplase

0.25mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
大体时间:At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

次要结果测量

结果测量
措施说明
大体时间
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
大体时间:At 24 hours

National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.

At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
大体时间:At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Distribution of Modified Rankin Scale (mRS)
大体时间:At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Percentage of Participants With Barthel Index Score ≥95
大体时间:up to 90 days

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.

up to 90 days
EQ-5D-5L score
大体时间:At Day 90±7 days

Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life)

At Day 90±7 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
大体时间:up to 36 hours

sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline.

up to 36 hours
All-cause mortality
大体时间:up to 90 days

All-cause mortality at 90 days

up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
大体时间:At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年12月19日

初级完成 (实际的)

2026年11月1日

研究完成 (实际的)

2026年11月1日

研究注册日期

首次提交

2025年11月21日

首先提交符合 QC 标准的

2025年12月7日

首次发布 (实际的)

2025年12月19日

研究记录更新

最后更新发布 (实际的)

2026年11月3日

上次提交的符合 QC 标准的更新

2026年11月1日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 2025IITDA10

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅